Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis AJ Templeton, MG McNamara, B Šeruga, FE Vera-Badillo, P Aneja, ... Journal of the National Cancer Institute 106 (6), dju124, 2014 | 3212 | 2014 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2396 | 2009 |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2362 | 2018 |
Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... Journal of Clinical Oncology 38 (3), 193-202, 2020 | 1645 | 2020 |
Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... JAMA oncology 6 (11), e204564-e204564, 2020 | 1111 | 2020 |
Organoid profiling identifies common responders to chemotherapy in pancreatic cancer H Tiriac, P Belleau, DD Engle, D Plenker, A Deschênes, TDD Somerville, ... Cancer discovery 8 (9), 1112-1129, 2018 | 945 | 2018 |
Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma A Bujold, CA Massey, JJ Kim, J Brierley, C Cho, RKS Wong, RE Dinniwell, ... Journal of Clinical Oncology 31 (13), 1631-1639, 2013 | 862 | 2013 |
Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis AM Horgan, E Amir, T Walter, JJ Knox Journal of clinical oncology 30 (16), 1934-1940, 2012 | 770 | 2012 |
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma RV Tse, M Hawkins, G Lockwood, JJ Kim, B Cummings, J Knox, ... Journal of clinical oncology 26 (4), 657-664, 2008 | 661 | 2008 |
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma AB Siegel, EI Cohen, A Ocean, D Lehrer, A Goldenberg, JJ Knox, H Chen, ... Journal of Clinical Oncology 26 (18), 2992-2998, 2008 | 614 | 2008 |
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial GK Abou-Alfa, P Johnson, JJ Knox, M Capanu, I Davidenko, J Lacava, ... Jama 304 (19), 2154-2160, 2010 | 570 | 2010 |
Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial KL Aung, SE Fischer, RE Denroche, GH Jang, A Dodd, S Creighton, ... Clinical Cancer Research 24 (6), 1344-1354, 2018 | 562 | 2018 |
Phase I study of individualized stereotactic body radiotherapy of liver metastases MT Lee, JJ Kim, R Dinniwell, J Brierley, G Lockwood, R Wong, ... Journal of clinical oncology 27 (10), 1585-1591, 2009 | 546 | 2009 |
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution M Chan-Seng-Yue, JC Kim, GW Wilson, K Ng, EF Figueroa, GM O’Kane, ... Nature genetics 52 (2), 231-240, 2020 | 545 | 2020 |
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ... European urology 66 (4), 704-710, 2014 | 526 | 2014 |
Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline JD Gordan, EB Kennedy, GK Abou-Alfa, MS Beg, ST Brower, TP Gade, ... Journal of Clinical Oncology 38 (36), 4317-4345, 2020 | 506 | 2020 |
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy TK Choueiri, W Xie, C Kollmannsberger, S North, JJ Knox, JG Lampard, ... The Journal of urology 185 (1), 60-66, 2011 | 444 | 2011 |
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with … RJ Motzer, CH Barrios, TM Kim, S Falcon, T Cosgriff, WG Harker, ... Journal of Clinical Oncology 32 (25), 2765-2772, 2014 | 415 | 2014 |
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first … JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox, GA Bjarnason, S Srinivas, ... The lancet oncology 16 (3), 293-300, 2015 | 395 | 2015 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial JJ Knox, D Hedley, A Oza, R Feld, LL Siu, E Chen, M Nematollahi, ... Journal of Clinical Oncology 23 (10), 2332-2338, 2005 | 386 | 2005 |